Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy
暂无分享,去创建一个
G. Remuzzi | A. Benigni | M. Abbate | C. Zoja | F. Piscitelli | V. Di Marzo | M. Locatelli | A. Bénardeau | D. Rottoli | G. Ottaviani | D. Corna | R. Verde | Jean-Michel Adam | J. Fingerle | Sebastian Villa | Valeria Nava | B. Rothenhaeusler | Daniela Rottoli
[1] S. Johansson,et al. O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .
[2] H. Parving,et al. Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy , 2015, Nature Reviews Nephrology.
[3] G. Godlewski,et al. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy , 2014, Proceedings of the National Academy of Sciences.
[4] G. Bruno,et al. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. , 2014, Kidney international.
[5] Mark E Molitch,et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.
[6] V. Marzo,et al. Endocannabinoid signalling and the deteriorating brain , 2014, Nature Reviews Neuroscience.
[7] C. Alpers,et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. , 2013, Journal of the American Society of Nephrology : JASN.
[8] M. Glass,et al. A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury , 2012, British journal of pharmacology.
[9] J. Kim,et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. , 2012, Endocrinology.
[10] Bancha Satirapoj,et al. Nephropathy in Diabetes , 2023, Experimental and Clinical Endocrinology & Diabetes.
[11] T. Ostenfeld,et al. A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction , 2011, The Clinical journal of pain.
[12] G. Bruno,et al. Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy , 2011, Diabetes.
[13] C. Alpers,et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[14] G. Remuzzi,et al. The RAAS in the pathogenesis and treatment of diabetic nephropathy , 2010, Nature Reviews Nephrology.
[15] H. Pan,et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. , 2010, Free radical biology & medicine.
[16] M. Rastaldi,et al. Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy , 2010, Diabetes.
[17] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[18] G. Camussi,et al. Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes , 2009, Diabetes.
[19] C. Chung,et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. , 2009, American journal of physiology. Renal physiology.
[20] Massimiliano Beltramo. Cannabinoid type 2 receptor as a target for chronic - pain. , 2009, Mini reviews in medicinal chemistry.
[21] V. Marzo. The endocannabinoid system in obesity and type 2 diabetes , 2008, Diabetologia.
[22] S. Friedman,et al. Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[23] K. Mackie,et al. CB2 cannabinoid receptor agonists attenuate TNF‐α‐induced human vascular smooth muscle cell proliferation and migration , 2008, British journal of pharmacology.
[24] V. Di Marzo. Endocannabinoids: synthesis and degradation. , 2008, Reviews of physiology, biochemistry and pharmacology.
[25] P. Dentelli,et al. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. , 2007, The American journal of pathology.
[26] M. Cooper,et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells , 2007, Diabetologia.
[27] K. Mackie,et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. , 2007, American journal of physiology. Heart and circulatory physiology.
[28] C. Ledent,et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells , 2007, Nature Medicine.
[29] G. Remuzzi,et al. Time to abandon microalbuminuria? , 2006, Kidney international.
[30] G. Remuzzi,et al. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. , 2006, Journal of the American Society of Nephrology : JASN.
[31] R. Trevisan,et al. Lipids and renal disease. , 2006, Journal of the American Society of Nephrology : JASN.
[32] G. Remuzzi,et al. Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. , 2006, The American journal of pathology.
[33] F. Mach,et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice , 2005, Nature.
[34] Liying Li,et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. , 2005, Gastroenterology.
[35] M. Mauer,et al. Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.
[36] F. Pi‐Sunyer,et al. Obesity and type 2 diabetes. , 2003, Endocrinology and metabolism clinics of North America.
[37] Giuseppe Remuzzi,et al. Nephropathy in Patients with Type 2 Diabetes , 2002 .
[38] Giuseppe Remuzzi,et al. Clinical practice. Nephropathy in patients with type 2 diabetes. , 2002, The New England journal of medicine.
[39] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[40] D. Heudes,et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.
[41] B. Brenner,et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. , 1999, Kidney international.
[42] I. Pawluczyk,et al. Cytokine interactions promote synergistic fibronectin accumulation by mesangial cells. , 1998, Kidney international.
[43] N. Perico,et al. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. , 1994, Journal of the American Society of Nephrology : JASN.
[44] E. Weibel. Practical methods for biological morphometry , 1979 .